RECURRENT CANCER
Clinical trials for RECURRENT CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CANCER trials appear
Sign up with your email to follow new studies for RECURRENT CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer study combining nanoparticles and proton therapy halted before it began
Disease control TerminatedThis study aimed to test a new treatment for people whose cancer came back after earlier radiation therapy. The approach combined special nanoparticles injected into the blood with targeted proton therapy to try to control the tumor. The study was withdrawn before any participant…
Matched conditions: RECURRENT CANCER
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated May 17, 2026 02:46 UTC
-
New immune drug IMA401 takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug called IMA401 in about 95 adults with advanced solid tumors (like lung or head/neck cancer) that came back or didn't respond to prior treatments. IMA401 is a special immune molecule that helps the body's T cells attack cancer cells. The stu…
Matched conditions: RECURRENT CANCER
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated May 17, 2026 02:40 UTC
-
New drug shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests a drug called CYH33 in people whose ovarian, fallopian tube, or peritoneal clear cell cancer has come back or not gone away. It is for those with a specific gene change (PIK3CA mutation) and who have already tried standard chemotherapy. The main goal is to see if…
Matched conditions: RECURRENT CANCER
Phase: PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:41 UTC